Radiation safety with Yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy

Seminars in Oncology Nursing

Volumn 20, Issue SUPPL. 1, 2004, Pages 14-19

  Hendrix, Carolyn ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; YTTRIUM; YTTRIUM 90;

B CELL LYMPHOMA; BODY FLUID; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; HEMATOLOGIC DISEASE; HUMAN; MEDICAL PRACTICE; METHODOLOGY; NURSE; NURSING; PATIENT EDUCATION; RADIATION EXPOSURE; RADIATION INJURY; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; REVIEW; RISK FACTOR; SAFETY; URINARY EXCRETION;

EID: 2942606149     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.soncn.2004.02.009     Document Type: Article

References (17)

1. Zevalin (ibritumomab tiuxetan) prescribing information. 2002;IDEC Pharmaceuticals Corporation, San Diego, CA
2. Potamianos S., Varvarigou A.D., Archimandritis S.C. Radioimmunoscintigraphy and radioimmunotherapy in cancer Principles and application. Anticancer Res. 20:2000;925-948
3. Kuzel T.M., Rosen S.T. Radioimmunotherapy of lymphomas and leukemias. Henkin R.E., Boles M.A., Dillehay G.L.,, et al. Nuclear Medicine. Vol 1:1996;594-601 Mosby-Year Book Inc, St Louis, MO
4. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 43:2002;267-272
5. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 27:2000;766-777
6. Wiseman G.A., Leigh B., Erwin W.D., et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer. 94:(suppl 4):2002;1349-1357
7. Wiseman G.A., White C.A., Sparks R.B., et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 39:2001;181-194
8. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol. 15:1999;1017-1025
9. Nuclear Regulatory Commission. Regulatory guide 8.3. 1997;Office of Nuclear Regulatory Research, US Nuclear Regulatory Commission, Washington, DC
10. Zanzonico P.B., Binkert B.L., Goldsmith S.J. Bremsstrahlung radiation exposure from pure beta-ray emitters. J Nucl Med. 40:1999;1024-1028
11. Wiseman G., Leigh B., Witzig T., et al. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. (abstr) Eur J Nucl Med. 28:2001;1198
12. 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma. J Nucl Med. 42:(suppl):2002;268P
13. Siegel J.A. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials Outpatient iodine-131 anti-B1 therapy. J Nucl Med. 39:(suppl 8):1998;28S-33S
14. 131I-tositumomab therapy. J Nucl Med. 43:2002;354-363
15. 131I tositumomab) prescribing information. 2003;Corixa Corporation, Seattle, WA
16. Harwood S.J., Gibbons L.K., Goldner P.J., et al. Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure. Cancer. 94:(suppl 4):2002;1358-1362
17. Seldin D.W. Techniques for using Bexxar for the treatment of non-Hodgkin's lymphoma. J Nucl Med Technol. 30:2002;109-114